The Life Sciences team advised Bicara Therapeutics in the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program BCA101 and its pipeline of investigational candidates to treat solid tumor cancers. The financing was co-led by Red Tree Venture Capital and RA Capital Management, with participation from existing investors, including F-Prime Capital, Eight Roads Ventures, Invus, Piper Heartland Healthcare Capital and Premji Invest. New investors include Omega Funds, Bioqube Ventures, Acorn Bioventures and Janus Henderson Investors.

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Bicara’s lead asset, BCA101, a first-in-class EGFR / TGF-β-trap bifunctional antibody, is currently enrolling patients in a Phase 1/1b study.

The Goodwin team was led by Gaby Morales-Rivera, Amarilice Young, Frank Qin, Samantha Jandl and Kingsley Taft and included Daniel Karelitz, Jason Osborn, Gozde Guckaya, Grace Wirth, Glynn Barwick, Kathryn Georgian and Aniko Bouley.

For additional details on the financing round, please read the press release.